Literature DB >> 18346008

Decrease in bacterial load versus resistance selection of pneumococcal subpopulations by beta-lactam physiological concentrations over time: an in vitro pharmacodynamic simulation.

Fabio Cafini1, Lorenzo Aguilar, David Sevillano, Maria-Jose Giménez, Luis Alou, Asuncion Fenoll, Olatz Echevarría, Martha Torrico, Natalia González, Pilar Coronel, Jose Prieto.   

Abstract

To investigate beta-lactam effects on Streptococcus pneumoniae-mixed cultures, a computerized pharmacodynamic model simulating over 24-hr concentrations obtained after several beta-lactam regimens was used. Strain 1 (no penicillin binding protein [PBP] mutations) and strain 2 (mutation in pbp1a) were penicillin/amoxicillin susceptible. Strain 3 (mutations in pbp1a, pbp2x, and pbp2b) and strain 4 (mutations in pbp1a, pbp2x, and pbp2b [10 changes]) were penicillin/amoxicillin resistant. Initial inoculum was approximately 6 x 10(6) CFU (colony forming units)/ml (with a 1:1:1:1 proportion of each strain). Population analysis profile was performed pre- and post-simulations. Strain 1 exhibited the best fitness (growth over 24 hr) in individual cultures, and strain 2 did so in mixed cultures in antibiotic-free simulations. In antibiotic simulations with the mixed inocula, penicillin/amoxicillin-susceptible strains were eradicated with all study drugs (time that concentrations exceed the minimal inhibitory concentration [T>MIC >or= 43%]). Penicillin-resistant strains showed different evolution depending on the antibiotic: (a) cefditoren produced >2 log(10) reduction of initial inocula at 12-24 hr (T>MIC >or=45%), with a remaining population growing in plates with >or=4 mg/L amoxicillin; (b) cefuroxime, cefixime, and cefaclor did not decrease initial inocula at 12-24 hr (T>MIC=0%), with minor subpopulations growing in plates with 4 mg/L amoxicillin; (c) amoxicillin produced 2.6 log(10) decrease of initial inocula at 12 hr (T>MIC=47.5%), but 1.1 log(10) increase of initial inocula at 24 hr, with a significant population growing in plates with 4 mg/L amoxicillin. Antibiotic activity against mixed inocula (susceptible and resistant strains) depends on intrinsic activity (as well as its subsequent pharmacodynamic activity: T>MIC against resistant strains), and on possible selection of intra-strain-resistant subpopulations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18346008     DOI: 10.1089/mdr.2008.0783

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  6 in total

Review 1.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

2.  Drug resistance in community-acquired respiratory tract infections: role for an emerging antibacterial.

Authors:  Lorenzo Aguilar; María-José Giménez; José Barberán
Journal:  Infect Drug Resist       Date:  2010-06-18       Impact factor: 4.003

Review 3.  Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults.

Authors:  María-José Giménez; Lorenzo Aguilar; Juan José Granizo
Journal:  Multidiscip Respir Med       Date:  2018-11-02

4.  Beta-lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamics.

Authors:  David Sevillano; Lorenzo Aguilar; Luis Alou; María-José Giménez; Natalia González; Martha Torrico; Fabio Cafini; Pilar Coronel; José Prieto
Journal:  PLoS One       Date:  2008-12-04       Impact factor: 3.240

5.  Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.

Authors:  Carlos A Rodriguez; Maria Agudelo; Yudy A Aguilar; Andres F Zuluaga; Omar Vesga
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

Review 6.  [Three keys to the appropriate choice of oral antibiotic treatment in the respiratory tract infections].

Authors:  R Menéndez; R Cantón; A García-Caballero; J Barberán
Journal:  Rev Esp Quimioter       Date:  2019-12-04       Impact factor: 1.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.